Announcements

December 5, 2017

OBI Pharma Inc. to attend Citi’s 2017 Global Healthcare Conference

[…]
November 28, 2017

OBI Pharma Inc. to attend the 2017 Asia Pacific Healthcare Forum, hosted by Goldman Sachs

[…]
November 16, 2017

SFIPC and OBI jointly agreed to withdraw the proceedings on Civil case regarding the dismissal of the Chairman of the company.

[…]
October 20, 2017

OBI Plans to Issue New Shares in Exchange for the AP Biosciences, Inc. Shares Owned by AbProtix,Inc, Subject to Regulatory Approval

[…]
October 20, 2017

Announcement on Change of the Accounting Officer

[…]
October 6, 2017

USPTO Approved the Patent Application for OBI-888 “Antibodies, pharmaceutical compositions and uses thereof”

[…]
September 25, 2017

Contract Signing with Pharmacore for the Contract Manufacturing of OBI-858

[…]
August 11, 2017

Announcement on Change of the Acting Spokesperson

[…]
August 11, 2017

Announcement on Change of the Head of Finance and Accounting

[…]
July 21, 2017

OBI Received a Civil Complaint from Taiwan Shilin District Court

[…]
July 12, 2017

Clarification on the news article by China Times

[…]
June 29, 2017

Clarification on the news article by Commercial Times

[…]
June 28, 2017

Important Resolutions of AGM 2017

[…]
June 11, 2017

Supplemental information on the approved application of Phase III clinical trial of OBI-822, the novel breast cancer drug, in China, US, and the EU

[…]
June 1, 2017

OBI Pharma Announces Acquisition of the Novel First-in-class Anti-Cancer Drug OBI-3424 from Threshold Pharmaceuticals to be Developed as Potential Anti-Cancer Therapy for Cancers with High AKR1C3

[…]
April 26, 2017

Announcement of explanation on the first instance judgment of the civil action between the Company against “Next Magazine”

[…]
April 17, 2017

Announcement of explanation on the Company’s criminal lawsuit against Next Magazine

[…]
April 6, 2017

OBI-833, the cancer therapeutic vaccine, has met the primary safety indicators in Phase I clinical trial for US and Taiwan

[…]
March 9, 2017

The board of directors have resolved not to distribute dividends

[…]
March 9, 2017

Announcement by the Company’s Board of Directors to convene the 2016 Annual General Shareholders’ meeting

[…]
March 9, 2017

OBI Pharma’s Board of Directors approves the announcement of the Company’s 2016 individual and consolidated financial statements

[…]
January 26, 2017

Supplemental Information: OBI-822 was approved to enter a Phase III clinical trial by the China Food and Drug Administration (CFDA)

[…]
January 25, 2017

OBI-822 was approved to enter a Phase III clinical trial by the China Food and Drug Administration (CFDA)

[…]
January 23, 2017

OBI Pharma Inc. announces the change of Chief Operating Officer

[…]
January 21, 2017

Clarification on the news article by Commercial Times

[…]
January 11, 2017

Clarification on the news article by United Daily News E-Paper

[…]
January 10, 2017

Clarification on the news article by Economic Daily News

[…]
January 9, 2017

Press release by the Shihlin District Prosecutors Office, Taiwan

[…]
December 30, 2016

Announcement of the signing of a Non-Binding Letter of Intent for OBI Pharma, Inc., to issue new shares to AbProtix, Inc., in exchange for up to 70% stake in AP Biosciences

[…]
December 22, 2016

Clarification on the news article by Economic Daily News

[…]
November 23, 2016

OBI Pharma granted patent approval for its 2nd Generation Active Immunotherapy Treatment by Taiwan and Australia

[…]
November 4, 2016

Clarification on the news article by Economic Daily News E-Paper

[…]
September 23, 2016

To clarify the media report

[…]
September 8, 2016

Additional charges on Next Digital Ltd., Hong Kong

[…]
September 7, 2016

The company was invited to participate in 17th Annual Asian Technology Conference organized by Credit Suisse

[…]
August 31, 2016

To clarify the media report

[…]
August 10, 2016

OBI Pharma Inc. announces the change of VP, Chief Medical Officer

[…]
July 1, 2016

To clarify the media report

[…]
June 27, 2016

Important resolutions of 2016 Annual General Shareholders’ Meeting

[…]
June 27, 2016

The Re-election of Directors at 2016 Annual General Shareholders’ Meeting

[…]
June 27, 2016

OBI Pharma ‘s 2016 Annual General Meeting has approved to release the newly elected Director from non-competition restriction

[…]
June 27, 2016

OBI Pharma, Inc. announces the re-appointment of Mr. Michael Chang as the Chairman of the Company.

[…]
June 15, 2016

The company was invited to participate in the overseas NDR (Non-Deal Roadshow) organized by Credit Suisse, and reported the study results presented in the 2016 ASCO.

[…]
June 14, 2016

OBI Pharma, Inc. will attend Cathay Securities’ Conference on June 16th

[…]
June 7, 2016

To correct the company’s Investor Conference presentation content on June 5 2016

[…]
June 6, 2016

To clarify the media report

[…]
June 5, 2016

The company will publish the clinical study data of the innovation research of OBI-822/OBI-821 for metastatic breast cancer patients at the annual meeting of 2016 ASCO.

[…]
May 30, 2016

Announcement of the Company holding investor presentation and Significant post press conference

[…]
May 30, 2016

Company will hold the Investor Conference

[…]
May 29, 2016

The company states the media’s reports on the related matters of American Society of Clinical Oncology (ASCO).

[…]
May 26, 2016

Media reports that Michael Chang, the chairman of the company, Amy Huang, the general manager and the staffs, six people in total, were guaranteed pending summons for alleged insider trading.

[…]
May 19, 2016

Publication of the Breast Cancer Study Abstract to be presented at ASCO 2016

[…]
May 13, 2016

Board Intentions to apply for long-term fund-raising plan

[…]
May 13, 2016

Supplementary notice on a company board resolution for the upcoming 2016 Annual Shareholders’ Meeting

[…]
May 3, 2016

Company reports outsider suspected of “rumor mongering” intended to manipulate company’s stock, and plans to take legal action against “NEXT Magazine”

[…]
April 22, 2016

OBI Pharma announces the end of the implementation for its first treasury share buyback program

[…]